SCHEMBL3563841

SCHEMBL3563841

Cc1ccccc1C(NC(=O)Nc1ccc(Cl)cc1)C(=O)Nc1ccc(C(=O)N2CCOC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.48
ALDH1A1 P00352 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 2/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
EPHX2 P34913 5/20 0.46
KDM4E B2RXH2 1/20 0.44
PHGDH O43175 1/20 0.44
TP53 P04637 1/20 0.43
F10 P00742 2/20 0.43
ADRB2 P07550 1/20 0.41
AKR1C3 P42330 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559218 0.88 ALDH1A1 (0.54) HPGDALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL3564959 0.84 HPGD (0.46) HPGDALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL8262956 0.80 MAPT (0.43) HPGDALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL3563838 0.80 ALDH1A1 (0.42) HPGDALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL5813908 0.80 CNR1 (0.53) ALDH1A1SMN1; SMN2MAPTNPC1LMNA
SCHEMBL3574057 0.79 F10 (0.70) F10
SCHEMBL8262955 0.76 F10 (0.45) ALDH1A1SMN1; SMN2HTTMAPTNPC1
SCHEMBL3557873 0.73 EP300 (0.54) ALDH1A1SMN1; SMN2MAPTNPC1KDM4E
SCHEMBL3568353 0.73 F10 (0.44) MAPTNPC1TP53F10
SCHEMBL3557437 0.73 CNR1 (0.52) ALDH1A1SMN1; SMN2MAPTNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 HPGD 441/4885ALDH1A1 1143/4885SMN1; SMN2 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.